Nasdaq · CIK 0001549595
NRIX Nurix Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $22.35 on Oct 9, 2026, +143% from the 52-week low and -20% from the high.
Last 90 days
Net insider value
-$320k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$320k by 2 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
NRIXOct 9, 2026 · close 22.35
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Nurix Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 1Weak | Christine Ring Chief Legal Officer sell | $134k 5,786 shares | -39% | +153% from low-17% from high | |
| 9Weak | Christine Ring Chief Legal Officer sell | $149k 5,787 shares | -39% | - | |
| 0Weak | Gwenn Hansen Chief Scientific Officer sell | $37k 1,452 shares | -1% | - | |
| 7Weak | Gwenn Hansen Chief Scientific Officer sell | $52k 4,308 shares | -6% | +35% from low-58% from high | |
| 30Weak | Hans van Houte Chief Financial Officer sell | $70k 6,198 shares | -16% | +28% from low-60% from high | |
| 21Weak | Gwenn Hansen Chief Scientific Officer sell | $39k 3,377 shares | -5% | +31% from low-59% from high | |
| 27Weak | Hans van Houte Chief Financial Officer sell | $28k 2,438 shares | -6% | +31% from low-59% from high | |
| 21Weak | Christine Ring Chief Legal Officer sell | $33k 2,894 shares | -7% | +31% from low-59% from high | |
| 8Weak | Gwenn Hansen Chief Scientific Officer sell | $73k 3,690 shares | -6% | - | |
| 0Weak | Christine Ring Chief Legal Officer sell | $125k 5,760 shares | -17% | - | |
| 9Weak | Christine Ring Chief Legal Officer sell | $82k 3,290 shares | -10% | - | |
| 26Weak | Hans van Houte Chief Financial Officer sell | $86k 3,546 shares | -10% | - | |
| 11Weak | Christine Ring Chief Legal Officer sell | $140k 5,760 shares | -17% | - | |
| 24Weak | Gwenn Hansen Chief Scientific Officer sell | $84k 3,437 shares | -6% | - | |
| 30Weak | Christine Ring Chief Legal Officer sell | $102k 4,182 shares | -13% | - | |
| 29Weak | Hans van Houte Chief Financial Officer sell | $58k 2,368 shares | -6% | - | |
| 0Weak | Christine Ring Chief Legal Officer sell | $82k 3,290 shares | -12% | - |
Transactions
The last 97 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +5,786 | $8.72 | $50k | 14,896 | 10 d ago |
| Oct 2, 2026 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,786 | $23.19 | $134k | 9,110 | 10 d ago |
| Oct 2, 2026 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,786 | $0.00 | $0 | 111,251 | 10 d ago |
| Sep 2, 2026 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +5,787 | $8.72 | $50k | 14,897 | 40 d ago |
| Sep 2, 2026 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,387 | $25.69 | $138k | 9,510 | 40 d ago |
| Sep 2, 2026 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -400 | $26.64 | $11k | 9,110 | 40 d ago |
| Sep 2, 2026 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,787 | $0.00 | $0 | 117,037 | 40 d ago |
| Sep 1, 2026 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +1,452 | $1.86 | $2,701 | 118,679 | 41 d ago |
| Sep 1, 2026 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,452 | $25.47 | $37k | 117,227 | 41 d ago |
| Sep 1, 2026 | Gwenn Hansen Chief Scientific Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,452 | $0.00 | $0 | 60,858 | 41 d ago |
| Sep 17, 2025 | Julia P Gregory director | MOption exercise Common Stock | +10,750 | $1.86 | $20k | 10,750 | Sep 17, 2025 |
| Sep 17, 2025 | Julia P Gregory director | MOption exercise Director Stock Option (right to buy)derivative | -10,750 | $0.00 | $0 | 22,583 | Sep 17, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 64,723 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 66,723 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 70,473 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +2,858 | $0.00 | $0 | 73,331 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock | -4,308 | $12.01 | $52k | 69,023 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 6,414 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 6,000 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 26,250 | Jul 30, 2025 |
| Jul 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -2,858 | $0.00 | $0 | 31,442 | Jul 30, 2025 |
| May 19, 2025 | Roy D. Baynes director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Paul M Silva director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Edward C Saltzman director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Judith A Reinsdorf director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Lori Anne Kunkel director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Anil Kapur director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | Julia P Gregory director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 19, 2025 | David L. Lacey director | AGrant or award Director Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 19, 2025 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -6,198 | $11.33 | $70k | 33,724 | May 2, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +1,924 | $0.00 | $0 | 34,462 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +2,886 | $0.00 | $0 | 36,610 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,206 | $0.00 | $0 | 59,143 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 61,143 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 38,610 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 36,462 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 64,893 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 40,212 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 42,360 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock | -3,377 | $11.50 | $39k | 61,516 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock | -2,894 | $11.50 | $33k | 37,318 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | SOpen-market sale Common Stock | -2,438 | $11.50 | $28k | 39,922 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -1,924 | $0.00 | $0 | 5,773 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -2,886 | $0.00 | $0 | 8,659 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,206 | $0.00 | $0 | 9,621 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 8,000 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 8,000 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 8,000 | Apr 30, 2025 |
| Apr 30, 2025 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 30,000 | Apr 30, 2025 |
| Apr 30, 2025 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 30,000 | Apr 30, 2025 |
| Apr 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 30,000 | Apr 30, 2025 |
| Mar 11, 2025 | Roy D. Baynes director | AGrant or award Director Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 13, 2025 |
| Feb 11, 2025 | Gwenn Hansen Chief Scientific Officer | AGrant or award Employee Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Feb 13, 2025 |
| Feb 11, 2025 | Gwenn Hansen Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +34,300 | $0.00 | $0 | 34,300 | Feb 13, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 53,877 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 55,877 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 59,627 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock | -3,357 | $19.81 | $66k | 56,270 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock | -333 | $20.33 | $6,768 | 55,937 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 12,827 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 10,000 | Jan 30, 2025 |
| Jan 30, 2025 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 33,750 | Jan 30, 2025 |
| Dec 2, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +5,760 | $1.86 | $11k | 33,844 | Dec 2, 2024 |
| Dec 2, 2024 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,760 | $21.73 | $125k | 28,084 | Dec 2, 2024 |
| Dec 2, 2024 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,760 | $0.00 | $0 | 59,746 | Dec 2, 2024 |
| Nov 4, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +3,290 | $9.57 | $31k | 31,374 | Nov 4, 2024 |
| Nov 4, 2024 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -3,290 | $25.00 | $82k | 28,084 | Nov 4, 2024 |
| Nov 4, 2024 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,290 | $0.00 | $0 | 96,389 | Nov 4, 2024 |
| Nov 1, 2024 | Hans van Houte Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -3,546 | $24.28 | $86k | 33,724 | Nov 1, 2024 |
| Nov 1, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +5,760 | $1.86 | $11k | 33,844 | Nov 1, 2024 |
| Nov 1, 2024 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,760 | $24.28 | $140k | 28,084 | Nov 1, 2024 |
| Nov 1, 2024 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,760 | $0.00 | $0 | 65,506 | Nov 1, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 48,357 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +2,886 | $0.00 | $0 | 33,888 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +1,924 | $0.00 | $0 | 26,516 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 28,516 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 35,888 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 50,357 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 32,266 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 54,107 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 39,638 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock | -4,182 | $24.31 | $102k | 28,084 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | SOpen-market sale Common Stock | -3,437 | $24.31 | $84k | 50,670 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | SOpen-market sale Common Stock | -2,368 | $24.31 | $58k | 37,270 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -2,886 | $0.00 | $0 | 14,431 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 16,034 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -1,924 | $0.00 | $0 | 9,621 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 12,000 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 12,000 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 12,000 | Oct 30, 2024 |
| Oct 30, 2024 | Christine Ring Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 37,500 | Oct 30, 2024 |
| Oct 30, 2024 | Gwenn Hansen Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 37,500 | Oct 30, 2024 |
| Oct 30, 2024 | Hans van Houte Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 37,500 | Oct 30, 2024 |
| Oct 15, 2024 | Anil Kapur director | AGrant or award Director Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Oct 16, 2024 |
| Oct 14, 2024 | Christine Ring Chief Legal Officer | MOption exercise Common Stock10b5-1 | +3,290 | $9.57 | $31k | 27,882 | Oct 15, 2024 |
| Oct 14, 2024 | Christine Ring Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -3,290 | $25.00 | $82k | 24,592 | Oct 15, 2024 |
| Oct 14, 2024 | Christine Ring Chief Legal Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,290 | $0.00 | $0 | 99,679 | Oct 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Roy D. Baynesdirector
- Julia P Gregorydirector
- Gwenn HansenChief Scientific Officer
- Anil Kapurdirector
- Lori Anne Kunkeldirector
- David L. Laceydirector
- Judith A Reinsdorfdirector
- Christine RingChief Legal Officer
- Edward C Saltzmandirector
- Paul M Silvadirector
- Hans van HouteChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.